The Mechanism of Silver Sulfadiazine Regulating the Cellular Immune Activity of Burn Sepsis

Abstract

Background: Silver sulfadiazine is effective in the treatment of sepsis in patients with burns, and its clinical value lies in studying the mechanism of its cellular immune activity. Methods: This study included 70 patients with sepsis following burn injury, with 35 patients treated with zinc sulfadiazine and 35 patients treated with silver sulfadiazine in our hospital. The inflammation status and treatment outcomes were compared in these two groups of patients. Results: The effective rate of treatment in the zinc sulfadiazine group was 80.00%, while the silver sulfadiazine group had a significantly higher effective rate of 94.29% (p < 0.05). The decrease in various inflammatory factors was greater in the silver sulfadiazine group than the zinc sulfadiazine group (p < 0.05). Patients in the silver sulfadiazine group also showed better improvement in vital signs (p < 0.05). The silver sulfadiazine group had a higher bacterial clearance rate, higher anti-infection efficiency, shorter duration of antibiotic use, and shorter hospital stay than the zinc sulfadiazine group (p < 0.05). The 14-day mortality rate was 5.7%, and the 28-day mortality rate was 8.6% in the silver sulfadiazine group. By contrast, the 14-day mortality rate was 8.6%, and the 28-day mortality rate was 14.3% in the zinc sulfadiazine group. The 14-day and 28-day mortality rates were significantly lower in the silver sulfadiazine group than in the zinc sulfadiazine group (p < 0.05). Conclusion: Silver sulfadiazine treatment significantly improves the patients quality of life, inhibits inflammatory reactions, and has a higher treatment Efficacy and positive clinical value. Therefore, silver sulfadiazine can be promoted to treat patients with burns and sepsis.